Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

CRANBURY, N.J., Nov. 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2012. 

Recent Highlights
On July 3, 2012, Palatin closed on a private placement of 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of its common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of its common stock. Aggregate gross proceeds to Palatin were $35,000,000, with net proceeds, after deducting offering expenses, of $34,407,446.

On September 27, 2012, at a special meeting Palatin stockholders voted to increase its authorized common stock from 100,000,000 to 200,000,000 shares, and Palatin filed a certificate of amendment with the Secretary of State of Delaware the same day. This satisfied certain contractual obligations relating to the Series B 2012 warrants in its 2012 private placement, so that interest will not be payable on the value of the Series B 2012 warrants and Palatin will not be required to redeem the Series B 2012 warrants for failure to increase the number of authorized shares.

On November 8, 2012, Palatin reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, demonstrate that women taking bremelanotide showed clinically meaningful and statistically significant increases
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Mesa, CA (PRWEB) , ... July 01, 2015 , ... ... traumatic brain injury (TBI) using single photon emission computed tomography (SPECT) according ... The study, which examined over 20,000 brain scans and is believed to be ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... Indianapolis, IN (PRWEB) , ... July 01, 2015 , ... ... the 2015 BIO International Convention in Philadelphia, PA. , The presentation took ... milestones and outlined the plans for the development of APX3330 for the treatment of ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... , , , , , ... Max-Planck-Institute for Marine Microbiology, Celsiusstr.1, 28359 Germany , ... Introduction , ... in coextraction of other soil components, mainly ...
... , , Bodo Eickhoff and Jrgen van der Bosch ... D-23845 Borstel, Germany. , Tel.: +49 4537 188458 Fax: +49 ... , Abstract , ... improving PCR efficiency: the TaqMaster. With this enhancer, an integral , ...
... , , , , Abstract ... an essential method that allows researchers to determine , the presence, ... the organism, tissue or cell of interest. The basic protocol involves the , ... , by amplification of the gene(s) of interest. Due to buffer ...
Cached Biology Technology:The Use of MasterTaq Polymerase for PCR with Humic Material-Contaminated , DNA 2The Use of MasterTaq Polymerase for PCR with Humic Material-Contaminated , DNA 3The Use of MasterTaq Polymerase for PCR with Humic Material-Contaminated , DNA 4The Use of MasterTaq Polymerase for PCR with Humic Material-Contaminated , DNA 5Enhancing PCR* Efficiency with MasterTaq 2Enhancing PCR* Efficiency with MasterTaq 3Enhancing PCR* Efficiency with MasterTaq 4Enhancing PCR* Efficiency with MasterTaq 5cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 2cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 3cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 4cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 5cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 6
(Date:6/23/2015)... Research and Markets( ... "Body-Worn Temperature Sensors Market - Global Industry ... - 2020" report to their offering. ... global body-worn temperature sensors market. The global body-worn ... basis of types, care setting, patient demographic, applications ...
(Date:6/17/2015)... und GERMANTOWN, Maryland , June 17, ... ®   Produktlinie mit DNA-Tests verbessert den Analyseprozess ... QGEN ; Frankfurt Prime Standard: QIA) hat heute ... der Produktlinie Investigator ® ... eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke bieten ...
(Date:6/16/2015)...  With the increasing number and severity of data ... The recent compromise of Federal employee data from ... within government agencies. HYPR Corp. announced today ... authenticator, has been submitted for testing and approval of ... for tamper proofing. The proliferation of ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... tuatara, evolutionary biologist, and ancient DNA expert, Professor David Lambert ... Ecology and Evolution recovered DNA sequences from the bones of ... found that, although tuatara have remained largely physically unchanged over ... a DNA level - faster than any other animal yet ...
... can be found in dye-sensitised solar cells. This type of ... for instance, plants and light-sensitive bacteria. Annemarie Huijser has succeeded ... cell, which is similar to Grtzel cells. Huijser will receive ... 25 March. The use of solar cells is increasing ...
... most cases of cervical cancer has a serious weakness which ... Human Papillomavirus (HPV), a virus which causes several types ... has developed clever ways of hiding in the body, but ... ability to trick the bodys first line of defence leaves ...
Cached Biology News:Tuatara, the fastest evolving animal 2Substantial improvement in essential cheap solar cell process 2Subterfuge, counter-surveillance and assassination: The body's fight with cervical cancer 2
... T4 DNA Ligase catalyzes the formation of ... between double-stranded DNAs with 3' hydroxyl and ... Ligase buffer optimizes ligation which can be ... acids are not substrates for this enzyme. ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Sulfadimethoxine (CH-2027)...
Biology Products: